Basilea developed Cresemba to treat diseases caused by fungal infections, and the Basel-based biopharmaceutical company has entered into several licence and distribution agreements for the anti-fungal medicine, including one with Astellas Pharma for the U.S.
Under the terms of the agreement, the two companies agreed on thresholds for U.S. sales figures. As Basilea announced today, U.S. sales exceeded the threshold, triggering the first milestone payment in the amount of 5 million Swiss francs.
Basilea is still eligible for additional sales milestone payments of up to 285 million francs.
“We are very pleased with the continued commercial success of Cresemba in the U.S. reflecting the medical need for agents treating invasive aspergillosis and invasive mucormycosis in adults and the increasing importance of Cresemba in the treatment of adults suffering from these potentially life-threatening invasive fungal infections that predominantly affect immunocompromised patients, such as patients with cancer and after transplantation,” said David Veitch, Chief Commercial Officer at Basilea.
